Abstract

Lung adenocarcinoma is a common histologic type of lung cancer with a high death rate globally. Increasing evidence shows that long non‐coding RNA H19 (lncRNA H19) and CDH1 methylation are involved in multiple tumours. Here, we tried to investigate whether lncRNA H19 or CDH1 methylation could affect the development of lung adenocarcinoma. First, lung adenocarcinoma tissues were collected to detect CDH1 methylation. Then, the regulatory mechanisms of lncRNA H19 were detected mainly in concert with the treatment of overexpression of lncRNA H19, siRNA against lncRNA H19, overexpression of CDH1 and demethylating agent A‐5az in lung adenocarcinoma A549 cell. The expression of lncRNA H19 and epithelial‐mesenchymal transition (EMT)‐related factors as well as cell proliferation, sphere‐forming ability, apoptosis, migration and invasion were detected. Finally, we observed xenograft tumour in nude mice so as to ascertain tumorigenicity of lung adenocarcinoma cells. LncRNA H19 and methylation of CDH1 were highly expressed in lung adenocarcinoma tissues. A549 cells with silencing of lncRNA H19, overexpression of CDH1 or reduced CDH1 methylation by demethylating agent 5‐Az had suppressed cell proliferation, sphere‐forming ability, apoptosis, migration and invasion, in addition to inhibited EMT process. Silencing lncRNA H19 could reduce methylation level of CDH1. In vivo, A549 cells with silencing lncRNA H19, overexpression of CDH1 or reduced CDH1 methylation exhibited low tumorigenicity, reflected by the smaller tumour size and lighter tumour weight. Taken together, this study demonstrates that silencing of lncRNA H19 inhibits EMT and proliferation while promoting apoptosis of lung adenocarcinoma cells by inhibiting methylation of CDH1 promoter.

Highlights

  • Lung adenocarcinoma, a frequently occurring subtype of lung can‐ cer, contributes to more than one million deaths on an annual basis globally.[1]

  • After incubation with DNA methyltransferase 1 (DNMT1) and DNA methyltransferase 3A (DNMT3A) antibodies, the results showed that the expression of long‐chain non‐coding RNAs (lncRNAs) long non‐coding RNA H19 (H19) and the expression of CDH1 promoter region in the DNMT1 and DNMT3A groups were significantly higher than those in the immunoglobulin G (IgG) group

  • We inves‐ tigated the role of lncRNA H19 and CDH1, methylation of CDH1 in lung adenocarcinoma and found that in contrary to CDH1, lncRNA

Read more

Summary

| INTRODUCTION

A frequently occurring subtype of lung can‐ cer, contributes to more than one million deaths on an annual basis globally.[1] Lung adenocarcinoma is characterized by a heterogeneous group of tumours stemming from the smaller airways and occurring in peripheral lung tissues.[2,3] Metastasis, considered as a leading le‐ thal cause of lung adenocarcinoma, can occur, only within months of diagnosis, in diverse organs in a swift manner.[4,5] Major therapies for lung adenocarcinoma conclude the use of erlotinib and gefitinib.[6] lung adenocarcinoma is highly refractory to conventional radio‐ and chemotherapies, which poses a challenge to the treatment efficacy.[7] Emerging evidence has reported the impli‐ cation of long‐chain non‐coding RNAs (lncRNAs) in the development as well as progression of lung cancer.[8]. We conducted this study to explore the effects of lncRNA H19 and CDH1 on lung adenocarcinoma with the involvement of methyl‐ ation of CDH1, with the hope to raise the life quality of patients with lung adenocarcinoma

| Ethics statement
| DISCUSSION
Findings
CONFLICTS OF INTEREST
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call